SCHEMBL684037

SCHEMBL684037

Cc1ccc(Cl)cc1N1CCN(Cn2cnc3c2c(=O)n(C)c(=O)n3C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.54
MAPK1 P28482 2/20 0.54
SMN1; SMN2 Q16637 4/20 0.52
HTT P42858 2/20 0.52
UBE2N P61088 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
GLA P06280 1/20 0.52
RXFP1 Q9HBX9 3/20 0.49
HTR7 P34969 1/20 0.49
HTR6 P50406 1/20 0.49
POLB P06746 1/20 0.48
ALDH1A1 P00352 2/20 0.48
ADORA2B P29275 5/20 0.47
MAPT P10636 1/20 0.47
TSHR P16473 2/20 0.46
TP53 P04637 1/20 0.46
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684024 0.90 HTR7 (0.51) LMNAMAPK1SMN1; SMN2L3MBTL1RXFP1
SCHEMBL682810 0.85 HTR7 (0.58) LMNASMN1; SMN2L3MBTL1RXFP1HTR7
SCHEMBL682817 0.84 LMNA (0.62) LMNAMAPK1SMN1; SMN2HTTUBE2N
SCHEMBL683660 0.84 HTR7 (0.51) LMNAMAPK1SMN1; SMN2L3MBTL1RXFP1
SCHEMBL683995 0.84 MAPK1 (0.72) LMNAMAPK1SMN1; SMN2HTTUBE2N
SCHEMBL684356 0.83 HTR7 (0.58) LMNAMAPK1SMN1; SMN2HTTUBE2N
SCHEMBL683998 0.82 HTR7 (0.57) LMNAMAPK1SMN1; SMN2L3MBTL1RXFP1
SCHEMBL682816 0.82 TSHR (0.55) LMNAMAPK1SMN1; SMN2L3MBTL1RXFP1
SCHEMBL682814 0.80 HTR7 (0.56) LMNAMAPK1SMN1; SMN2HTTUBE2N
SCHEMBL11157185 0.80 HTR7 (0.62) LMNAMAPK1RXFP1HTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF LMNA 2155/4885MAPK1 470/4885SMN1; SMN2 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.